Table 1.

Randomized controlled trials in major depressive episode (MDE) with mixed features in major depressive disorders

Study	Duration (wk)	Medication	Primary measure	Definition	Results	Remark
Suppes et al.11) (2016)	6	Lurasidone (20–60 mg/day, n=109) vs. placebo (n=100)	Changes from baseline in MADRS	MDE with 2–3 manic symptoms	−20.5 vs. −13.0 (effect size=0.80)	m/c adverse events: nausea (6.4 % vs. 2.0%), somnolence (5.5% vs. 1.0%)
Post-hoc studies
Tsai et al.12) (anxiety)
Swann et al.13) (irritability)
Sramek et al.14) (post-menopause)
Goldberg et al.15) (3 mo extension study)
Patkar et al.16) (2015)	13	Ziprasidone (20 mg bid–160 mg/d) vs. placebo (n=49)	Changes from baseline in MADRS	MDE with at least 3 of bipolarity	Nonsignificant (−1.57±1.67 in ziprasidone, p=0.48)	Crossover study

MADRS, Montgomery–Åsberg Depression Rating Scale; m/c, most common; bid, twice a day.